Value-Based Pricing

Value-Based Pricing (VBP) aligns the price of a treatment with the value it provides to patients, healthcare systems, and society. Across multiple indications, a single price may not accurately reflect a medicine’s value, Indication-Based Pricing (IBP) allows different prices to be set for different indications.

Publication

Understanding the Full Value of Long-Acting Therapies: less is more?

7 May 2025

Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.

Publication

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

14 April 2025

Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.

A gold padlock
Publication

Unlocking the Value of Combination Therapies

9 July 2024

Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.

A blue padlock
Publication

A Framework for Value-aligned Pricing of Combination Therapies

25 June 2024

Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.

Insights

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

16 January 2024

Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.

Capturing the Broader Value of Antibiotics
Publication

Capturing the Broader Value of Antibiotics

23 November 2023

The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.

Insights

OHE’s AMR consultation response

21 November 2023

This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
Publication

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

8 November 2023

NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.